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KLK13 is a kallikrein-related peptidase preferentially expressed in tonsils, esophagus, testis, salivary
glands and cervix. We report the activation of KLK13 by kosmotropic salts and glycosaminoglycans and
its substrate speciﬁcity by employing a series of ﬁve substrates derived from the ﬂuorescence resonance
energy transfer (FRET) peptide Abz-KLRSSKQ-EDDnp. KLK13 hydrolyzed all these peptides only at basic
residues with highest efﬁciency for R; furthermore, the S3 to S20 subsites accepted most of the natural
amino acids with preference also for basic residues. Using a support-bound FRET peptide library eight
peptide substrates were identiﬁed containing sequences of proteins found in testis and one with myelin
basic protein sequence, each of which was well hydrolyzed by KLK13. Histatins are salivary peptides
present in higher primates with broad antifungal and mucosal healing activities that are generated from
the hydrolysis from large precursor peptides. KLK13 efﬁciently hydrolyzed synthetic histatin 3 exclu-
sively at R25 (DSHAKRHHGYKRKFHEKHHSHRGYR25YSNYLYDN) that is the ﬁrst cleavage observed inside
the salivary gland.
In conclusion, the observed hydrolytic activities of KLK13 and its co-localization with its activators,
glycosaminoglycans in the salivary gland and high concentration of sodium citrate in male reproductive
tissues, indicates that KLK13 may play a role in the defense of the upper digestive apparatus and in male
reproductive organs.
 2011 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
The tissue kallikrein members represent a cluster of 15 serine
peptidases of chymotrypsin-like S1A family clan PA(S) localized in
the human chromosome locus 19q13.4, and present a high degree
of identity [1e7]. Human kallikrein-related peptidase 13 (KLK13) is
one of these peptidases that is expressed in many tissues withine] 2,4-dinitrophenyl); Abz,
iazole; TBTU, 2-(1H-benzo-
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nder the Elsevier OA license.preferences in glandular epithelia, tonsils, esophagus, trachea,
testis, salivary glands, vagina and cervix [8e10]. The physiological
roles of KLK13 remain unknown, in contrast to KLK1 that is
involved in kinin release [11]; KLK3 hydrolyzes seminogelin I and II
in semen and contributes to its liquefaction after ejaculation
[12,13]; KLK4 in prostate activates KLK3 [14,15], is modulated by
a speciﬁc zinc binding site [16] and is involved in dental enamel
formation [17]; KLK6 activates PAR2 and cleaves glutamatergic
receptors and myelin basic protein [18e22]; KLK5 and KLK7 are
involved in skin desquamation (for a recent review see [23]) and
KLK8 participates in human epidermis and sweat in a proteolytic
cascade contributing to the skin barrier [24]. The associations of
KLK13 with some pathologies were earlier reported, and include
psoriasis vulgaris and atopic dermatitis [25] (where the peptidase is
expressed in signiﬁcant amounts), it is observed to be a favorable
prognosis marker in ovarian cancer [26], is expressed in high levels
in some types of salivary gland tumors [27], is down regulated
in testicular cancer [28,29] and is also reported to degrade the
extracellular matrix [30].
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tial to identify their roles in mammalian organisms, to aid in the
development of selective assays, and to guide the design of novel
inhibitors. The substrate speciﬁcity of KLK13 was earlier investigated
by screening of ﬂuorogenic 7-amino-4-carbamoylcoumarin positional
scanning-synthetic combinatorial libraries modiﬁed at the P1 to P4
positions [31] and KLK13 was observed to have selectivity of the S1
subsite for R, preference for hydrophobic amino acids by the S2 and S4
subsites, and S3 selectivity mainly for R (Schechter and Berger
nomenclature [32]). Though these synthetic combinatorial libraries
have provided valuable information about the speciﬁcity of numerous
peptidases [33,34] they are restricted to the non-prime side of the
peptidases, its application can be impaired for peptidases where the
active site requires extended prime site substrates. In addition,
cleavages of these substrates other than at the amino site of the 7-
amino-4-methylcoumarin group (peptidyl-Y-AMC) are not detected
with this library.
Glycosaminoglycans (GAGs) and kosmotropic salts such as
sodium citrate and sodium sulfate were reported to strongly acti-
vate the hydrolytic activities of KLK3 and KLK6 [18,35,36] in
contrast to KLK1 that is inhibited by salts [37]. In the present work
we examined the modulation of salts and GAGs on hydrolytic
activity of KLK13 and its S3 to S20 subsite substrate speciﬁcity taking
as reference the ﬂuorescence resonance energy transfer (FRET)
peptide Abz-KLRSSKQ-EDDnp (Abz ¼ ortho-aminobenzoic acid and
EDDnp ¼ N-[2,4-dinitrophenyl]-ethylenediamine), which was
designed based on previously reported subsite requirements of
KLK1 and KLK6 [18]. Five series of analogs of this peptide were
synthesized with substitution of each amino acid, except Gln, and
assayed as substrates of KLK13.
Histatins are a class of salivary peptides present in higher
primates, rich in basic amino acids [38] and have broad antifungal
activity [39e41]. The systematic search by tandem mass spectros-
copy of human saliva showed that the generation of histatin 3-
related peptides resulted mainly from the action of trypsin-like
proteases, and the ﬁrst cleavage being at R25 (DSHAKRHHGYKRKF-
HEKHHSHRGYR25YSNYLYDN) [42]. The selectivity of KLK13 for
hydrolysis at R and K and its co-localizationwith histatins in salivary
glands [10] prompted us to examined the hydrolytic activity of
KLK13 on synthetic histatin 3 that is mainly processed in human
saliva into histatin 6 (DSHAKRHHGYKRKFHEKHHSHRGYR25) and
then to histatin 5 by removing of C-terminal R25 [42]. Due to
selectivity of KLK13 to cleave at basic amino acids, the kininogenase
activity was also evaluated using low molecular weight (LMW)
kininogen, and a synthetic human kininogen fragment, Abz-MIS-
LMKRPPGFSPFRSSRI-NH2 that contains a bradykinin sequence.Fig. 1. (A) Puriﬁed recombinant KLK13 analysis by 15% SDS-PAGE in reducing conditions. La
and 4-Mature forms of KLK13 isolated by C4. (B) C4 reverse phase HPLC separation of doubWe further tried to ﬁnd other possible candidates as natural
substrates for KLK13 using a support-bound FRET peptide library
prepared on PEGA resin (a beaded polyethylene glycol dimethyla-
crylamide copolymer) by the process of split-combine synthesis,
which results in a single peptide sequence on each resin bead
[43e46]. The FRET peptide bound to a resin bead when hydrolyzed
by the peptidase turned the bead ﬂuorescent; such beads were
manually picked up and the remained peptide in the bead was
sequenced by Edman degradation methodology. The identiﬁed
peptides were synthesized and the cleavage sites by KLK13 were
subsequently determined in solution and the kinetic parameters for
their hydrolysis were evaluated.
2. Materials and methods
2.1. Recombinant KLK13
Mature KLK13 was expressed and puriﬁed from a baculovirus/
insect cell line system as previously described [22]. Brieﬂy, the KLK13
gene which encodes for the mature form of KLK13 was inserted in
frame, C-terminal of an enterokinase propeptide. To facilitate the
puriﬁcation procedure, a 6 His-tag was also included on the N-
terminal side of the enterokinase propeptide. The puriﬁcation took
advantage of the His-tag by Ni-NTA afﬁnity chromatography. After
puriﬁcation, KLK13 was activated by extended (i.e. 24 h) incubation
with enterokinase at 1:100 ratio of enterokinase:pro-KLK13 (w/w).
Hydrolysis of the enterokinase propeptide proceeded to apparent
completion and the released propeptide and enterokinase were
removed from the mature KLK13 by size exclusion chromatography.
The ﬁnal yield of puriﬁed mature KLK13 was typically 20e25 mg per
liter of culture. The ﬁnal purity of mature KLK13 was assessed by
Coomassie Brilliant Blue staining of a 15% SDS-PAGE gel, N-terminal
sequencing, and mass spectrometry, and yielded a purity of at least
98% with no visible degradation (Fig. 1A) and the correct mature N-
terminus. The puriﬁed, mature form of KLK13 remained a single chain
and migrated as closely-spaced doublet bands under both reducing
and non-reducing conditions. The results of N-terminal sequencing
revealed that both bands had identical termini consistent with
mature KLK13 (VLNTXGTSGFLP). The 5th cycle of the reaction did not
give an amino acid assignment, and this is presumably due to
glycosylation of Asn. The doublet bands were separated by Phe-
nomenex C4 reverse phase HPLC (Fig. 1-B) and analyzed by MALDI-
TOF mass spectrometry (Fig. 1-C), and the peak of each fragment
presented molecular masses 29,213 and 30,270 Da, respectively.
These values are higher than the calculated mass of un-modiﬁed
KLK13 presumably due to the result of heterogeneous glycosylationnes: 1-Molecular weight marker; 2-Mature form of KLK13 with doublet fragments; 3-
let fragment. (C) MALDI-TOF analysis of KLK13 fragments.
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hexose units). Both fragments exhibited similar enzymatic activity
against Tos-GPR-AMC. Molar concentration of active KLK13 was
determined by titration with MUGB (4-Methylumbelliferyl p-guani-
dinobenzoate hydrochloride) by spectroﬂuorimetric tritation as
previously described [47]. Bovine myelin basic proteinwas purchased
from (AbD Serotec, Raleigh, NC, USA).
2.2. Peptide synthesis
All FRET peptides and histatin-3 were obtained by solid-phase
peptide synthesis as previously described [48,49] and using the
Fmoc-procedure in an automated bench-top simultaneous multiple
solid-phase peptide synthesizer (PSSM 8 system from Shimadzu,-
Tokyo, Japan). The peptides were synthesized in TGR-resin (loading
0.2 mmol/g) using HBTU/HOBt as coupling reagent and the cleavage
of peptide-resin was accomplished with TFA:anisol:EDT:water
(85:5:3:7). All peptides obtained were puriﬁed by semi-preparative
HPLC on an Econosil C-18 column. The molecular weight and purity
(94% or higher) of synthesized peptides were checked by amino acid
analysis and MALDI-TOF mass spectrometry, using a Microﬂex e LT
mass spectrometer (Bruker e Daltonics, Billerica, MA, USA). Stock
solutions of the peptides were prepared in DMF and the concen-
trations were measured spectrophotometrically using the molar
extinction coefﬁcient of 17,300 M1 cm1 at 365 nm.
2.3. Synthesis of support-bound FRET peptide library
The syntheses of libraries were carried out manually as previ-
ously described [46]. Brieﬂy, the libraries were synthesized on 1 g of
PEGA1900 resin [50] in a 20 column Teﬂon synthesis block, using
protected Fmoc amino acids. The resinwas evenly distributed in the
20 wells of the Teﬂon synthesis block, and the Fmoc groups were
removed. Prior to coupling the Fmoc amino acids (1 equiv.) were
pre-activated with HOBt (1 equiv.), TBTU (1 equiv.) and NMM
(2 equiv.) in DMF (1 ml) for 6 min and the activated amino acids
were added, one to each of the 20 wells. After the completion of the
coupling, the block was ﬁlled with DMF up to 1 cm above the top of
the wells and inverted, and the resin was mixed vigorously by
agitation for 30 min in the mixing chamber. The block was again
inverted, evenly distributing the resins into the wells for washing
and removal of the Fmoc group. This procedure was repeated for
the incorporation of all the randomized positions. After the
randomized positions, the Fmoc-K(Abz-Boc) and Fmoc-K(Dnp)
were incorporated. The side chain protecting groups were
removed by treatment with a mixture of TFA:thioanisole:ethane-
dithiol:water (87:5:5:3) for 8 h. The resin was washed with 95%
acetic acid (4), DMF (4), 5% DIPEA in DMF (3), DMF (3), DCM
(6) and dried under vacuum.
2.4. Glycosaminoglycans
Size-deﬁned (12,000 Da) bovine lung heparin (The Upjohn Co.)
was prepared by using a size exclusion column approach [51];
heparan sulfate (16,000 Da) from bovine lung was a generous gift
from Dr. P. Bianchini (Opocrin Research Laboratories, Modena,
Italy); dermatan sulfate (12,000 Da) and chondroitin sulfate
(25,000 Da) were purchased from Seikagaku Kogyo Co. (Tokyo,
Japan).
2.5. Kinetic measurements
The FRET peptides were assayed in a Shimadzu RF-1501 spec-
troﬂuorometer, at 35 C. The assays were performed in 50 mM Tris,
1 mM EDTA, pH 7.5 and 35 C (the temperature of highest activitywas at 38 C) with 0.5 mM heparin or 1.5 M sodium citrate. The
enzymes were pre-incubated in the assay buffer for 3 min before
the addition of substrate. Fluorescence changes were monitored
continuously at lex ¼ 320 nm and lem¼ 420 nm.When ﬂuorogenic
MCA peptides were used, the excitation and emission wavelengths
were changed to lex ¼ 380 and lem ¼ 460 nm, respectively. The
enzyme concentrations for initial rate determinations were chosen
at a level intended to hydrolyze less than 5% of the added substrate
over the time course of data collection. The slope of the generated
ﬂuorescence signal was converted into micromoles of substrate
hydrolyzed per minute based on a calibration curve obtained from
the complete hydrolysis of each peptide.
2.6. Support-bound FRET peptide library screening
For all assays, the library beads were washed with water (3)
and the assay buffer (3) before the addition of the enzyme. The
reactions were stopped by dilution with 3 M HCl, and the mixtures
were washed thoroughly until pH 5e6 was reached. The beads
were transferred to a glass dish and inspected by ﬂuorescence
microscopy (Stereomicroscope Stemi-Zeiss), and the ﬂuorescent
beads were collected and transferred to a TFA-treated cartridge
ﬁlter for on-resin sequence analysis. The amino acid sequence and
cleavage point were determined by Edman degradation using
a PPSQ/23 protein sequencer (Shimadzu, Japan). KLK13was assayed
as follows: 20 mg of resin in 50 mM Tris, 1 mM EDTA, pH 7.5, at
25 C for 5 h with 75 nM of enzyme. The identiﬁed peptide
sequences susceptible to hydrolysis by KLK13 were synthesized as
FRET Abz-peptidyl-Q-EDDnp peptides and assayed in solution with
the enzyme.
2.7. Digestion of myelin basic Protein by KLK13
Bovine myelin basic protein (MBP) was added to KLK13 at
a 2000:1 mass ratio in 50 mM Tris and 1 mM EDTA, pH 7.5. This
mixture was incubated at 35 C, and time points were taken at 2, 4,
8, and 12 h. The MBP and degradative fragments were resolved
using Tricine SDS-PAGE (16.5%) and developed by Comassie-Blue
and two bands were isolated and the N-terminal sequenced by
Edman degradation to identify the cleavage sites.
2.8. Kininogenase activity of KLK13
Low molecular weight human kininogen (LK) was purchased
from Calbiochem. The ability of KLK13 to cleave the human LK was
evaluated incubating 1 ml of LK (100 mg/ml) and KLK13 (1.8 nM) in
reaction mixtures containing 50 mM Tris, 0e1.5 M sodium citrate,
pH 7.5, at 35 C for 4 h. Ethanol (3:1, v/v) was added, and the
mixture was centrifuged at 1000  g for 15 min. The kinin content
in the supernatant was measured by radioimmunoassay, as previ-
ously described [52] KLK1 was also assayed as comparative control.
3. Results
3.1. Conditions for high KLK13 activity
The FRET peptide Abz-KLRSSKQ-EDDnp was taken as the initial
substrate to search for the best conditions required for efﬁcient KLK13
hydrolytic activity. The peptide Abz-KLRSSKQ-EDDnpwas hydrolyzed
only at the ReS bond, and this activity of KLK13 at pH 7.5 was highly
activated by sodium citrate or sodium sulfate, as shown in Fig. 2A.
High activationwas also observedwith heparin up to 0.5 mM (Fig. 2-B)
and chondroitin and dermatan sulfate also activated KLK13 but at
concentration range 20e40 mM (data not showed). KLK13 bound
to heparineSepharose resin and was eluted with 100 mM NaCl,
Fig. 2. (A) Activation of KLK13 by sodium citrate (C) and sodium sulfate (,). (B) Activation of KLK13 by heparin (C) pH proﬁles of KLK13 activity in the presence of sodium citrate
(:), heparin (-) and only with buffer (C). The reactions were performed in 50 mM Tris, 1 mM EDTA, pH 6.5e9.0, using as substrate 7.5 mM Abz-KLRSSKQ-EDDnp, and
[E] ¼ 3.8 nmol at 35 C.
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heparin and KLK13 that was not observed with KLK1 and KLK6. The
pH proﬁles of KLK13 activities in the presence of 1 M sodium citrate
and heparin are showed in Fig. 2-C. The KLK13 activity was reduced
close to zero in the presence of 50 mM Tris HCl (with no sodium
citrate or heparin). The presence of NaCl, KCl, MgCl2 and CaCl2 up to
1 M concentration did not activate the enzyme.Table 1
Kinetic parameters for the hydrolysis by KLK13 of the reference peptides Abz-
KLRSSKQ-EDDnp and Abz-KLKSSKQ-EDDnp in the presence of heparin and sodium
citrate.
Activator kcat (s)1 Km (mM) kcat/Km (mM s)1
Abz-KLRYSSKQ-EDDnp
0.5 mM heparin 3.2  0.1 2.2  0.1 1455  80
1.5 M sodium citrate 3.4  0.2 1.2  0.05 2834  204
Abz-KLKYSSKQ-EDDnp
0.5 mM heparin 0.50  0.03 31  2 16  3
1.5 M sodium citrate 0.10  0.01 5.3  0.3 19  2
The reactions were performed in 50 mM Tris, 1 mM EDTA, pH 7.5, 0.5 mM heparin
and [KLK13] ¼ 3e10 nmol at 35 C. The parameters and the standard errors were
obtained from three determinations. The errors associated to kcat/Km were obtained
by error propagation of the kcat and Km errors.3.2. Substrate speciﬁcity of KLK13 using FRET peptides derived
from Abz-KLRSSKQ-EDDnp
The peptide Abz-KLRSSKQ-EDDnp was taken as reference, and
a series of ﬁve related FRET peptides were synthesized and assayed
as substrates for KLK13 in 50 mM Tris at pH 7.5 and 35 C in the
presence of 0.5 mM heparin, and for some peptides the assays were
done in the presence of 1.5M sodium citrate. The speciﬁcity of the S1
subsite was explored with the peptide series Abz-KLXSSKQ-EDDnp
(where X¼ R, K, F, Y, M, L, V,W, D, E, G, H, I, N, P, Q, S, and T). Only the
peptides Abz-KLRYSSKQ-EDDnp and Abz-KLKYSSKQ-EDDnp (i.e.
X ¼ R or X ¼ K) were hydrolyzed and only at the peptide bonds ReS
and KeS, respectively. The kinetic parameters of these hydrolyses in
the presence of heparin and sodium citrate at pH 7.5 are presented
in Table 1. All other peptides were resistant in both conditions up to
60 nM of KLK13. These results indicate that the S1 subsite of KLK13
has a very restricted speciﬁcity for basic amino acids. The resistance
to hydrolysis of peptide Abz-KLNSSKQ-EDDnp contrasts with the
reported hydrolysis of peptides containing N at the P1 position in the
screening of ﬂuorogenic 7-amino-4-carbamoylcoumarin positional
scanning-synthetic combinatorial libraries [31].
The FRET peptides in the series Abz-XLRSSKQ-EDDnp, Abz-
KXRSSKQ-EDDnp, Abz-KLRXSKQ-EDDnp and Abz-KLRSXKQ-EDDnp,
were synthesized in order to explore the speciﬁcity of the subsites
S3, S2, S10 and S20, respectively. The kinetic parameters for their
hydrolysis by KLK13 are shown in Tables 2 and 3. All the peptides of
the four series were hydrolyzed only at the ReS (or ReX) bond.
The parameters for the hydrolysis of the series Abz-KXRSSKQ-
EDDnp (Table 2) shows that the S2 subsite of KLK13 did not
present restricted speciﬁcity; however, higher kcat/Km values were
observed with substrates containing basic or hydrophobic amino
acids at the P2 position. Similarly, an S3 subsite preference for basic
and hydrophobic residues was observed as demonstrate from the
parameters of hydrolysis of the series Abz-XLRSSKQ-EDDnp
(Table 2). However, the peptide with the negatively charged
residue E at the P3 position was resistant to hydrolysis.
The kinetic parameters for the hydrolysis of the peptide series
Abz-KLRXSKQ-EDDnp (Table 3) show that the S10 subsite of KLK13has a particular preference for K in contrast to R, as indicated by the
kcat/Km value for the hydrolysis of the peptide Abz-KLRYKSKQ-
EDDnp that is 170-times higher than that of the peptide Abz-
KLRYRSKQ-EDDnp. The second best substrate of this series contains
N and the peptides with F, S and H at the P10 position were still
efﬁciently hydrolyzed. Not unexpectedly, the peptide with X ¼ P at
the S10 subsite was completely resistant to hydrolysis due to the
imide bond of P. The kinetic parameters for hydrolysis of the series
Abz-KLRSXKQ-EDDnp (Table 3) also show that the S20 subsite of
KLK13 does not have restricted speciﬁcity but does present pref-
erence for the basic amino acid R, and the resistance to hydrolysis of
the peptide Abz-KLRSEKQ-EDDnp indicates that the S20 of KLK13
does not accepted negative charge.3.3. Screening of support-bound FRET peptide library
The peptides selected from the screening of this library were
synthesized as FRET Abz-peptidyl-Q-EDDnp peptides and assayed
with KLK13. Their sequences and velocities of hydrolysis in the
presence of 1 M sodium citrate are shown in Table 4. The suscep-
tibility to hydrolysis by KLK13 of the selected peptides was higher
in the presence of sodium citrate than in the presence of 50 mM
TriseHCl, and most of these peptides were cleaved at the carboxyl
side of R. Only two peptides were cleaved at K and each with lower
velocities. It is noteworthy that the basic amino acids have signif-
icant frequency in all positions besides the P1 position and eight out
of twenty sequences were found in proteins from testis.
One human myelin basic protein sequence (GPVKKRNM) was
found as a potential substrate of KLK13 in the support-bound
peptide library that was conﬁrmed by the hydrolysis of the FRET
Table 2
Kinetic parameters for the hydrolysis by KLK13 of the series of peptides Abz-
KXRSSKQ-EDDnp and Abz-XLRSSKQ-EDDnp in the presence of heparin (i.e. evalu-
ating the speciﬁcity of S2 and S3 subsites, respectively).
X kcat (s)1 Km (mM) kcat/Km (Mm s)1
Abz-KXRSSKQ-EDDnp (P2)
R# 5.60  0.03 1.74  0.03 3218  58
(0.50  0.05) (0.74  0.02) (676  70)
I 8.84  0.04 2.96  0.05 3027  53
K 8.96  0.05 4.74  0.03 1890  16
L(ref) 3.22  0.02 2.28  0.03 1412  21
P 7.56  0.07 5.23  0.01 1445  14
V 6.05  0.04 5.05  0.05 1200  12
F 7.04  0.05 7.04  0.06 1000  11
E e e 860*10
Y 6.9  0.1 10.7  0.1 635  11
H 2.9  0.1 5.7  0.1 509  20
M e e 531*12
T 4.9  0.08 8.9  0.02 550  9
S 5.7  0.06 11.0  0.07 518  10
A 4.0  0.03 8.5  0.02 469  4
Q 1.6  0.07 6.0  0.04 267  12
G 2.0  0.06 12.7  0.02 161  5
N 1.1  0.1 9.9  0.1 111  10
AbzeXLRSSKQ-EDDnp (P3)
R 6.45  0.05 3.92  0.04 1135  17
K(ref) 3.20  0.02 2.25  0.03 1422  20
I 10.6  0.1 7.80  0.02 1359  13
F 7.24  0.05 6.9  0.1 1049  17
V e e 800*25
H 6.32  0.03 8.0  0.1 790  11
A 6.06  0.04 10.3  0.1 588  7
Q 5.51  0.01 10.40  0.06 529  3
N 5.03  0.03 14.6  0.1 344  3
L 3.86  0.03 12.6  0.1 306  3
E e NH e
The reactions were performed in 50 mM Tris, 1 mM EDTA, pH 7.5, 0.5 mM heparin
and [KLK13] ¼ 3e10 nmol at 35 C. The values in parenthesis were obtained in the
presence of 1 M sodium citrate. Reference peptide Abz-KLRSSKQ-EDDnp (ref).
*These kcat/Km values were obtained in pseudo-ﬁrst order conditions because the Km
values were too high and impaired the kinetic parameter determination due to
inner ﬁlter of ﬂuorescence. #Two cleavages was observed with Abz-KR*RYSSKQ-
EDDnp, the cleavage indicated by Y was 80% and the cleavage indicated by * was
20%. NH ¼ no hydrolysis. The parameters and the standard errors were obtained
from three determinations. The errors associated to kcat/Km were obtained by error
propagation of the kcat and Km errors.
Table 3
Kinetic parameters for the hydrolysis by KLK13 of the series of peptides Abz-
KLRXSKQ-EDDnp and Abz-KLRSXKQ-EDDnp in the presence of heparin (i.e. evalu-
ating the speciﬁcity of S10 and S20 subsites, respectively).
X kcat (s)1 Km (mM) kcat/Km (mM.s)1
Abz-KLRXSKQ-EDDnp (P10)
K 26.6  0.1 3.10  0.02 8581  64
(0.55  0.01) (0.93  0.01) (591  12)
N 11.8  0.1 5.33  0.03 2224  23
F 4.1  0.06 2.40  0.01 1708  26
S(ref) 3.21  0.02 2.24  0.03 1433  21
H 4.24  0.05 3.00  0.06 14,013  33
Q 4.8  0.1 7.9  0.1 607  15
A 2.46  0.01 4.06  0.05 606  8
I 0.60  0.01 1.35  0.02 444  10
V 1.52  0.03 3.60  0.02 422  9
L 1.20  0.03 3.81  0.01 314  8
G 2.05  0.06 10.20  0.02 200  6
R 0.34  0.02 5.9  0.1 58  10
(3.07  0.05) (1.54  0.03) (2000  51)
E e NH e
Abz-KLRSXKQ-EDDnp (P20)
R 8.9  0.1 1.03  0.01 8640  128
L 29.5  0.1 7.60  0.03 3881  20
F 14.8  0.1 4.02  0.03 3681  37
Q 17.0  0.1 8.30  0.04 2048  16
A 6.9  0.05 3.83  0.02 1816  16
S(ref) 3.2  0.02 2.20  0.03 1454  22
V 6.9  0.03 7.02  0.05 982  8
H 2.9  0.07 3.45  0.03 840  24
N 4.5  0.07 6.00  0.05 750  13
G 3.3  0.02 5.34  0.07 618  9
P 0.7  0.01 6.42  0.02 109  9
I 0.5  0.02 5.54  0.02 91  3
E e NH e
The reaction conditions were as in Table 2 and NH ¼ no hydrolysis. The values in
parenthesis were obtained in the presence of 1 M sodium citrate.
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ﬁnding and the detection of KLK13 in neurons and glial cells [8]
prompted us to assay commercially available bovine myelin basic
protein as a substrate for KLK13. Fig. 3 shows the SDS-PAGE of the
highly digested myelin basic protein and at least two cleavage sites
were indentiﬁed, namely.YGGRYASDYK. and .PRHRYDTGI.3.4. Hydrolysis of histatin 3 by KLK13
Histatin 3 was synthesized Abz at the N-terminal end in order to
increase the detection of the peptide and its products of hydrolysis
by HPLC analysis with ﬂuorescence detector (Abz-DSHAKRHH-
GYKRKFHEKHHSHRGYR25SNYLYDN). The time course of its hydro-
lysis by KLK13 in the presence of 0.5 mM heparin is shown in Fig. 4
with the HPLC proﬁles of the reaction mixture sampled at different
times. The hydrolysis of histatin 3 occurred only at the R25eS
peptide bond, with a velocity ¼ 35 nmol/min/nmol of enzyme. It is
noteworthy that even after 24 h of reaction only the R25eS peptide
bond was cleaved, which indicates a remarkable speciﬁcity of
KLK13 for this segment of histatin 3. Similar results were obtained
by the activation of KLK13 with 1 M sodium citrate (data not
shown).3.5. Kininogenase activity of KLK13
Low molecular weight human kininogen (LK) incubated with
KLK13 released a low amount of kinin comparedwith the activity of
KLK1. This low kininogenase activity of KLK13 was dependent on
the presence of sodium citrate as shown in Fig. 5. We also examined
the KLK13 hydrolysis time course of the human kininogen fragment
Abz-MISLMKRPPGFSPFRSSRI-NH2 which was rapidly cleaved at the
ReS bond with release of Abz-MISLMKRPPGFSPFR-OH, and this
fragment was subsequently slowly hydrolyzed at the K-R bondwith
low yield of bradykinin (Fig. 6). These results were conﬁrmed by
KLK13 hydrolysis in the presence of 1 M sodium citrate of the
peptide Abz-GFSPFRYSSRIQ-EDDnp (kcat¼ 0.3 s1, Km¼ 0.6 mMand
kcat/Km ¼ 500 mM1.s1) and by the very slow hydrolysis of the
peptide Abz-MISLMKYRPQ-EDDnp.4. Discussion
The hydrolytic activity of KLK13 is substantially activated by the
kosmotropic salts sodium citrate and sodium sulfate, and in their
absence the KLK13 activity was very low with most of the assayed
peptide substrates. Although this observation may be puzzling, the
also high activities of KLKs 3 and 6 in the presence of sodium citrate
suggest that this KLKmay be effectively modulated by in vivomicro-
environment concentrations of ions. The macromolecular crowding
concept seems to be adequate to interpret the activation of the KLKs
3, 6 and 13 by high sodium citrate concentrations. The macromo-
lecular crowding obtained by high salt concentration was reported
to compact KLK3 [35] with reduction of surface-to-volume ratio,
Table 4
Sequences and hydrolysis of FRET peptides obtained from support-bound peptide library.
Sequences Velocity of Hydrolysis Human protein containing the peptide sequence (with database access)
Abz-KLRYSSKQ-EDDnp 130 Reference peptide
Abz-HK*TRYSEAQ-EDDnp 120 c114 SLIT-like testicular protein isoform (XP_002344102.1)
Abz-GPKQRYSR*RQ-EDDnp 50 Bromodomain adjacent to zinc ﬁnger domain protein 1A (Q9NRL2 (BAZ1A_human)
Abz-EVK*RYKTYQ-EDDnp 50 Histone-lysine N-methyltransferase (Q8IZD2 MLL5_human)
Abz-RQIRYKNEQ-EDDnp 40 Ankyrin repeat domain-containing protein (Q8N7Z5 ANR31_human)
Abz-GPNLRYARQQ-EDDnp 30 1) Sperm-associated antigen 17 (Q6Q759.1jSPG17_human)
2) Cancer/testis antigen 75 (Q6PK30.2jCT75_human)
Abz-GPKLYRRYIQ-EDDnp 20 Not found
Abz-TMVK*QARYKQ-EDDnp 20 Neutrophil cytosolic factor 4 (Q15080 NCF4_human)
Abz-GPVK*KRYNMQ-EDDnp 20 1) Spermatogenesis-associated protein (Q8NHS9jSPT22_human)
2) Myelin basic protein (MBP) (spjP02686jMBP_human)
Abz-AMER*ARYMQ-EDDnp 20 Sarcoma antigen NY-SAR-22 (Q86WF6_ human)
Abz-GPRMYRYKLQ-EDDnp 15 IQ motif containing GTPase activating protein (Q59HA3_ human)
Abz-GPRYVGGRVQ-EDDnp 15 Testis-speciﬁc Y-encoded-like protein (Q86VY4.2jTSYL5_human)
Abz-NKRYHPNAQ-EDDnp 15 Dual speciﬁcity testis-speciﬁc protein kinase 1 (Q15569 TESK1_human)
Abz-GPVAK*NRYSQ-EDDnp 15 1) Testis-expressed sequence 2 protein (Q8IWB9jTEX2_human)
2) Spermatogenic leucine zipper protein 1 (Q9BXG8jSPZ1_human)
Abz-HPRYAMR*RQ-EDDnp 10 1) T-complex-associated testis-expressed protein 1 (Q5JU00.1_human)
2) Cancer/testis antigen 42 (Q9BXT5.1jTEX15_human)
Abz-GPFAYQRYHQ-EDDnp 10 Not found
Abz-GPRYQVK*KFQ-EDDnp 10 Glutamate receptor 4 precursor (P48058jGRIA4_human)
Abz-GPRYSK*EIQ-EDDnp 5 Not found
Abz-NWR*ERYSLQ-EDDnp 5 Not found
Abz-GPKYKYYSIAQ-EDDnp 5 Cancer/testis antigen 42 (Q9BXT5.1jTEX15_human)
Abz-EPHMKYHQ-EDDnp 5 Neuropeptide Y receptor type (Q15761.1jNPY5R_human)
Conditions of hydrolysis: 50 mM Tris, pH 7.5, 35 C, [KLK13] ¼ 8.7 nM and a ﬁxed concentration of 10 mM of each peptide. Y indicates the preferred cleavage site (at least 90%)
and * indicates the a secondary cleavage site. The only exception was the peptide Abz-GPKYKYYSIAQ-EDDnp where both cleavage sites were equally hydrolyzed. Velocity
unit ¼ pmol/min  nmol E.
D. Andrade et al. / Biochimie 93 (2011) 1701e17091706which results in an active conformation of the enzyme; for review
and concept explanation of macromolecular crowding see [53].
Sodium citrate is present in normal prostate tissue and seminal ﬂuid
in high concentration [54,55,56], and it can be a potential physio-
logical modulator of KLK13 activity since it is also present in pros-
tate, testis and in female reproductive organs [10]. In addition,
KLK13 was reported to activate KLK2 and KLK3 by cleaving the ReI
bond in the common sequence .IQSRYIVGG. [57], that is in
accordance to our observed KLK13 speciﬁcity, and then sodium
citrate can also modulate the activation cascade these kallikreins in
prostate. The hydrolysis of histatin 3 exclusively at R25 (Fig. 4) by
KLK13 activated by heparin seems to be a relevant observation dueFig. 3. SDS-PAGE of myelin basic protein digested by KLK13 in 18% polyacrylamide gel, dev
0.5 mM heparin, pH 7.5 at 35 C. At least two cleavage sites were indentiﬁed: .YGGRYASDto the presence of high concentration chondroitin sulfate in tonsils
[58] and in saliva [59] that also activates KLK13 (data not showed).
The S1 subsite of KLK13 presented strict speciﬁcity for the basic
amino acids R and K, with large preference for R compared to K as
shown by the kcat/Km value for the cleavage of Abz-KLRYSSKQ-
EDDnp that was two orders of magnitude higher than that of Abz-
KLKYSSKQ-EDDnp. These observations are in agreement with the
screening of the support-bound peptide library that selected only
peptides hydrolyzed at R or K residues (Table 4). The subsites S2, S3,
S10 and S20 of KLK13 also accepted basic amino acids as indicated
from kinetic parameters of hydrolysis of the FRET peptides series
derived from Abz-KLRSSKQ-EDDnp. The efﬁcient hydrolysis of theeloped by Coomassie Blue. The hydrolysis was performed in 50 mM Tris, 1 mM EDTA,
YK. and .PRHRYDTGI. by N-terminal sequencing using Edman degradation.
Fig. 4. Hydrolysis of histatin 3 by KLK13 in the presence of heparin. Reaction conditions 50 mM Tris, 1 mM EDTA pH 7.5 [E] ¼ 13 nmol with 0.5 mM heparin. The substrate is 38 mM
Abz labeled histatin 3 (Abz-DSHAKRHHGYKRKFHEKHHSHRGYR25YSNYLYDN-NH2). The products were identiﬁed by mass spectrometry.
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commercial peptide Z-RR-MCAwould be a convenient substrate for
KLK13, however this peptide was cleaved at the ReR bond instead
of at the R-MCA bond as detected by HPLC analysis of the hydrolysis
products. This result suggests that for a short peptide constituted of
a pair of R ﬂanked by hydrophobic groups put the R residues at S1
and S10 subsites of KLK13.
The identiﬁcation of eight substrates of KLK13 in the screening
of the support-bound peptide library with sequences that are
present in proteins from testis appears to be a signiﬁcant obser-
vation because only in testis were found ﬁve splice variants in
addition to the normal KLK13. In testicular cancer only normal
KLK13 is expressed, while KLK13 variants are expressed only in
normal testis [28,29]. At the moment it would be very speculative
to correlate possible physiological or pathological roles of the
hydrolysis by KLK13 of the testis proteins indicated in Table 4,
however this ﬁnding merits further investigation. The identiﬁca-
tion in the support-bound peptide library of a peptide withFig. 5. Kininogenase activity of KLK13 towards human LMW kininogen in the presence
of different concentrations of sodium citrate. Stoichiometric amounts (16 pmol) of
KLK13 and kininogenwere used in the absence or presence of citrate ions (0.1e1.25 M).
The buffer system used was 50 mM Tris, pH 7.5 containing 1 mM EDTA. The reaction
mixtures, in a ﬁnal volume of 80 mL, were incubated for 4 h at 35 C.sequence of myelin basic protein as a potential substrate of KLK13
was conﬁrmed by the efﬁcient hydrolysis of bovine equivalent
protein (Fig. 3). It is possible that KLK13 plays a role in the cleavage
of myelin basic protein because this kallikreinwas found in neurons
and glial cells by immunohistochemical technique [8]. In addition,
glycosaminoglycans that activate KLK13 are associated with central
nervous system remodeling, development, and disease (for reviews
see [60,61]).
The co-localization of KLK13 and its activators in different
tissues reported above incite questions about how the in vitro
conditions used in the present work would mimic physiological or
pathological conditions in vivo. Our data spanned a large range of
concentration of the activators that possibly included those found
in the normal or pathological tissues.
The kininogenase activity of KLK13 on human LMWkininogen is
very poor compared with that of KLK1, although KLK13 was able to
digest it. As shown in the hydrolysis of the human kinogen frag-
ment peptide Abz-MISLMKRPPGFSPFRSSRI-NH2 (Fig. 6) the low
kininogenase activity is due to the resistance of hydrolysis of the
KeR bond in the N-terminal side of the bradykinin sequence in the
kininogen.Fig. 6. Time course of hydrolysis by KLK13 of the human kininogen fragment Abz-
MISLMKRPPGFSPFRSSRI-NH2. The substrate and their products of hydrolysis were
quantiﬁed by HPLC and are shown as percentage of product formation or substrate
degradation. The products were identiﬁed by mass spectrometry.
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KLK13 cleaved peptide substrates only at the carboxyl side of
basic residues and with a large preference for R compared to K; in
contrast the S3, S2, S10and S20 subsites do not present strict speci-
ﬁcity but accept basic amino acids. The high activation of KLK13 by
sodium citrate that is present in normal prostate tissue and seminal
ﬂuid in high concentration, the presence of KLK13 in the male and
female reproductive organs and the presence of proteins that are
potential substrates of KLK13 substrates in testis suggest that KLK13
plays roles in the physiology of these organs that could be modu-
lated by sodium citrate. Finally, besides the hydrolysis of myelin
basic protein our data strongly suggest that the KLK13 expressed in
salivary glands and/or tonsils is involved in the initial cascade of
histatin 3 processing and can be involved in the defense of the
upper digestive apparatus.
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